Literature DB >> 2778489

Epidural compression from metastatic tumor with resultant paralysis.

F L Ampil1.   

Abstract

To determine the value of the usually given 'urgent' palliative radiotherapy in paraplegic patients with epidural compression from metastatic tumor, 20 consecutive cases treated between 1981 and 1986 were retrospectively analyzed. Bronchogenic and prostatic carcinoma were the more common extraspinal sources of metastasis. Epidural metastasis involved the thoracic spine in most cases. The onset of neurological symptomatology was frequently within two weeks prior to hospitalization. The majority of the subjects received at least 3000 cGy given in 10 to 15 fractions. Symptomatic (pain relief) response rate was 78 (7/9) percent. The observed period of survival averaged 2.5 months after treatment. This study reaffirmed the little chance for recovery of lost limb(s0 motor function. None of the patients (most of whom were paraplegic from two to 90 days pre-irradiation) became ambulatory including the two in whom irradiation was administered within 24 hours from the onset of paraplegia.

Entities:  

Mesh:

Year:  1989        PMID: 2778489     DOI: 10.1007/BF00165097

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Spinal cord compression produced by extradural malignant tumours; early recognition, treatment and results.

Authors:  E H BOTTERELL; G W FITZGERALD
Journal:  Can Med Assoc J       Date:  1959-05-15       Impact factor: 8.262

2.  The results of laminectomy for compression of the cord or cauda equina by extradural malignant tumour.

Authors:  A J Hall; N N Mackay
Journal:  J Bone Joint Surg Br       Date:  1973-08

3.  Role of surgery in the treatment of spinal cord compression by metastatic neoplasm.

Authors:  W A White; R H Patterson; R M Bergland
Journal:  Cancer       Date:  1971-03       Impact factor: 6.860

4.  Acute spinal cord compression paralysis.

Authors:  I M Tarlov
Journal:  J Neurosurg       Date:  1972-01       Impact factor: 5.115

5.  Treatment by radiotherapy of spinal cord compression due to extradural metastases.

Authors:  F R Khan; A S Glicksman; F C Chu; J J Nickson
Journal:  Radiology       Date:  1967-09       Impact factor: 11.105

6.  Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy.

Authors:  R F Young; E M Post; G A King
Journal:  J Neurosurg       Date:  1980-12       Impact factor: 5.115

7.  Early diagnosis of metastases in the epidural space.

Authors:  E Longeval; J Hildebrand; G H Vollont
Journal:  Acta Neurochir (Wien)       Date:  1975       Impact factor: 2.216

8.  Epidural spinal metastases: factors related to selection of cases for decompressive laminectomy.

Authors:  M L Apuzzo; M H Weiss; H V Minassian
Journal:  Bull Los Angeles Neurol Soc       Date:  1977-07

9.  Neurological results in spinal cord metastases.

Authors:  M Baldini; G P Tonnarelli; L Princi; C Vivenza; V Nizzoli
Journal:  Neurochirurgia (Stuttg)       Date:  1979-09

10.  Early diagnosis of spinal epidural metastases.

Authors:  L D Rodichok; G R Harper; J C Ruckdeschel; A Price; G Roberson; K D Barron; J Horton
Journal:  Am J Med       Date:  1981-06       Impact factor: 4.965

View more
  3 in total

Review 1.  The use of radiation in the management of spinal metastases.

Authors:  C M Faul; J C Flickinger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 2.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

3.  Reducing the overall treatment time for radiotherapy of metastatic spinal cord compression (MSCC): 3-year results of a prospective observational multi-center study.

Authors:  Dirk Rades; Fabian Fehlauer; Axel Hartmann; Ingeborg Wildfang; Johann H Karstens; Winfried Alberti
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.